A Long-term Phase III Study of TK-041 in Patients with Perennial Allergic Rhinitis
Phase 3
- Conditions
- Perennial allergic rhinitis
- Registration Number
- JPRN-jRCT2080222900
- Lead Sponsor
- TEIKOKU SEIYAKU CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Diagnosed with perennial allergic rhinitis and the symptoms will be expected to continue for more than 12 weeks after the start of treatment
Exclusion Criteria
Nose diseases (nasal polypus, nasal septum curvature symptom, hypertrophic rhinitis, etc.) or infectious diseases (upper respiratory tract inflammation, sinusitis, infectious rhinitis, infectious ophthalmopathy, etc.) that may interfere with the evaluation
Hypersensitivity to antihistamine drugs or study drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method